Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 3;29(19):4689.
doi: 10.3390/molecules29194689.

Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

Giuliana Greco  1   2 , Maria Grazia Sarpietro  2   3
Affiliations
Review

Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

Giuliana Greco et al. Molecules. .

Abstract

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system that leads to neurological dysfunctions and severe disabilities. It is worth noting that conventional pharmacotherapy is poorly selective and causes toxicity problems and several systemic side effects. Thus, there is a need to develop new approaches to this medical challenge. The use of nanocarriers for drug delivery represents a good strategy to overcome several issues such as high therapeutic drug doses with side effects, such as diarrhea, nausea, and abdominal pain, and drug degradation processes; in addition, nanocarriers can provide controlled and targeted drug release. This review describes the application of liposomes for the delivery of pharmaceutical actives to target MS. Firstly, MS is explained. Then, liposomes are described along with their preparation, characterization, and stability. The literature about the use of liposomes for the treatment of MS is then analyzed.

Keywords: BBB; EAE models; drug delivery; liposomes; multiple sclerosis; nanocarriers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Risk factors for MS.
Figure 2
Figure 2
Clinical courses of MS. Adapted from [20].
Figure 3
Figure 3
Classification of liposomes basing on size and lamellarity. Small unilamellar vesicles (SUVs) are less than 100 nm in diameter; large unilamellar vesicles (LUVs) are between 100 and 1000 nm; giant unilamellar vesicles (GUVs) are larger than 1 μm. Oligolamellar vesicles (OLVs) contain between two and five concentric bilayers; MLVs contain more than five concentric bilayers. Multivesicular vesicles (MVVs) encapsulate multiple non-concentric bilayer vesicles. Adapted from [46].
Figure 4
Figure 4
Liposome preparation by thin-film hydration.
Figure 5
Figure 5
Representative studies in MS involving liposomes.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Dymek M., Sikora E. Liposomes as Biocompatible and Smart Delivery Systems–the Current State. Adv. Colloid Interface Sci. 2022;309:102757. doi: 10.1016/j.cis.2022.102757. - DOI - PubMed
    1. Shah S., Dhawan V., Holm R., Nagarsenker M.S., Perrie Y. Liposomes: Advancements and Innovation in the Manufacturing Process. Adv. Drug Deliv. Rev. 2020;154–155:102–122. doi: 10.1016/j.addr.2020.07.002. - DOI - PubMed
    1. Akbarzadeh A., Rezaei-Sadabady R., Davaran S., Joo S.W., Zarghami N., Hanifehpour Y., Samiei M., Kouhi M., Nejati-Koshki K. Liposome: Classification, Preparation, and Applications. Nanoscale Res. Lett. 2013;8:102. doi: 10.1186/1556-276X-8-102. - DOI - PMC - PubMed
    1. Number of People with MS|Atlas of MS. [(accessed on 4 July 2024)]. Available online: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.
    1. Hassani A., Corboy J.R., Al-Salam S., Khan G. Epstein-Barr Virus Is Present in the Brain of Most Cases of Multiple Sclerosis and May Engage More than Just B Cells. PLoS ONE. 2018;13:e0192109. doi: 10.1371/journal.pone.0192109. - DOI - PMC - PubMed

LinkOut - more resources